Commercialization Agreement with ElancoOTTAWA, CANADA, December 8, 2006. Chemaphor Inc., a biotechnology research and
development company announced today that it has reached a collaborative research,
license and commercialization agreement with Elanco Animal Health (“Elanco”), a
division of Eli Lilly and Company (NYSE:LLY) to license its OxBC product technology
(“OxBC”). The agreement establishes the framework for Chemaphor and Elanco to
develop and potentially commercialize products for use in poultry and other food animal
species using OxBC technology. Under the agreement, Chemaphor may receive
technology access fees, regulatory milestone payments and royalties from OxBC sales.
If that got you excited, it's old news and you haven't done your DD.
They later ended the agreement in Chemaphor's favor, giving them all rights to OxBC thus allowing them to expand to other markets, like companion animal, health and beauty, and cancer research; and not bound within Elanco's contract.
At the time of this NR, CFR traded just above .40 and an Eli Lilly division was entering a commercialization agreement with them; a high profile company like LLY interested in CFR?? That's got to account for something. Who's next?
With the current controversy over the feed animal feed industry, we can see CFR is in the lead with an alternative to the current garbage they use, and thanks to Inopsy's excellent posts, everyone here should be well educated on the subject.
Very low risk here.... An R&D company with a division that's starting to produce revenues (internationally soon) + Government backing = minimal dilution.
I think we'll have another leg up to at least .20 soon, then .30, then .... who knows...they didn't put that restriction on those warrants for no reason ;). Last week's trading didn't even put the TA into overbought territory, so there's still more room before the SP hits a ceiling.
Buy the ticket, take the ride.
It'll be fun.